Status In progress
Decision Selected
Process CDF Review
ID number 1635

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Takeda UK (ixazomib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Myeloma UK
Professional groups Royal College of Pathologists
  Royal College of Physicians
  UK Myeloma Forum
Comparator companies Advanz pharma (dexamethasone) – confidentiality agreement not signed, not participating
  Aspen (dexamethasone) – confidentiality agreement not signed, not participating
  Aspire pharma (bortezomib, dexamethasone) – confidentiality agreement not signed, not participating
  Celgene (lenalidomide)
  Consilient health (dexamethasone) – confidentiality agreement not signed, not participating
  Dr Reddy’s laboratories (bortezomib) – confidentiality agreement not signed, not participating
  Focus Pharmaceuticals (dexamethasone) – confidentiality agreement not signed, not participating
  Glenmark pharmaceuricals (dexamethasone) – confidentiality agreement not signed, not participating
  Janssen-Cilag (bortezomib)
  Martindale pharma (dexamethasone) – confidentiality agreement not signed, not participating
  Mylan (bortezomib) – confidentiality agreement not signed, not participating
  Rosemont pharmaceuticals limited (dexamethasone) – confidentiality agreement not signed, not participating
  Secura Bio (panobinostat)
  Teva (dexamethasone)
  Thornton & Ross (bortezomib) – confidentiality agreement not signed, not participating
  Zentiva (bortezomib) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
04 May 2022 In December 2021 we informed you that further evidence was required to develop recommendations for this technology. Work to progress this appraisal is continuing and we will provide a further update by 31 May 2022.
21 December 2021 Further evidence is required to develop recommendations for this technology. As a result, the appraisal been paused and we will provide an update by 31 March 2022. During the pause, patient access via the Cancer Drugs Fund will continue uninterrupted.
15 December 2021 Committee meeting: 1
14 July 2021 Following the need for further analyses, this appraisal has been rescheduled. The first committee meeting has now been scheduled for 15 December 2021.
10 March 2021 Invitation to participate
10 March 2021 In progress. ITP now due

For further information on our processes and methods, please see our CHTE processes and methods manual